XXII (22nd Century Group) Gross Profit Margin

22nd Century Group (XXII) is a biotech developer of low-nicotine tobacco, protected by unique patents and FDA approval. Gross profit margins demonstrate the efficiency of the model, where the current mark is -11.10. Moderate business growth relies on seed licensing, while the development of the R&D pipeline ensures a steady expansion of the raw material base for commercial product supplies.
Analytical breakdowns and data insights for company 22nd Century (XXII)

An objective assessment of the investment attractiveness of 22nd Century Group (XXII) requires a deep fundamental analysis of production efficiency. Gross margin measures the profit share after deducting direct costs, allowing monthly gross margin data to serve as a gauge of the business's ability to control expenses. For an issuer monetizing proprietary low-nicotine raw materials, growth in this metric confirms the high market value of its biotechnologies and the quality of the generated capital.